ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT04956276
- Locations
- 🇺🇸
Clinical Study Site, Riverside, California, United States
Study of ALXN2050 in Healthy Adult Participants of Japanese Descent
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04952545
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04940559
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04935294
- Locations
- 🇺🇸
Clinical Trial Site, Saint Paul, Minnesota, United States
Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04933682
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT04920370
- Locations
- 🇬🇧
Clinical Study Site, London, United Kingdom
Study of a Single Dose of Danicopan in Healthy Participants
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04889677
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
Study of Multiple Doses of Danicopan in Healthy Participants
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04889690
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
Study of Radiolabeled Danicopan in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C]-Danicopan
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04889391
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
COVID-19 Soliris Expanded Access Protocol
- Conditions
- Covid19
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT04802083